G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/50 (2006.01)
Patent
CA 2690568
Novel methods and drug products for treating inflammatory joint diseases such as rheumatoid arthritis and associated arthritides are disclosed. The methods and products employ various serum markers of bone and cartilage metabolism or destruction, including cartilage oligomer matrix protein (COMP) and Receptor activator of NFB ligand (RANKL), as biomarkers to assess the effect of IL-17A antagonists on joint destruction in inflammatory joint diseases.
L'invention porte sur de nouveaux procédés et de nouveaux produits médicamenteux pour traiter des maladies inflammatoires des articulations telles que la polyarthrite rhumatoïde et les arthrites associées. Les procédés et produits emploient divers marqueurs de sérum du métabolisme ou de la destruction des os et du cartilage, comprenant une protéine de matrice oligomère de cartilage (COMP) et un activateur de récepteur du ligand NFB (RANKL), en tant que biomarqueurs pour évaluer l'effet d'antagonistes IL-17A sur la destruction de l'articulation dans des maladies inflammatoires d'articulations.
Bowman Edward Paul
Chao Cheng-Chi
Chen Shi-Juan
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Schering Corporation
LandOfFree
Joint destruction biomarkers for anti-il-17a therapy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Joint destruction biomarkers for anti-il-17a therapy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Joint destruction biomarkers for anti-il-17a therapy of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1892795